News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG Molecular Diagnostics Achieves ISO 13485:2003 Certification
Demonstrating Internationally Recognized Standards for Quality Management in Provision of Medical Devices and Related Services TUCSON, Ariz. (July 30, 2012) – HTG Molecular Diagnostics, a privately-held company providing products for gene expression profiling, has achieved ISO 13485:2003
View HTML
Toggle Summary HTG Molecular Diagnostics Licenses Breast Cancer Marker Patent Portfolio from Merck
TUCSON, Ariz. (July 11, 2012) – HTG Molecular Diagnostics, a privately held, Tucson-based developer of mRNA and miRNA gene expression-based cancer diagnostics, has been granted a non-exclusive license to develop, manufacture, and commercialize breast cancer diagnostic tests under Merck’s patent
View HTML
Toggle Summary HTG Molecular Diagnostics Hires Vice President of Molecular Diagnostic Sales
TUCSON, Ariz. (June, 2012) – HTG Molecular Diagnostics, a privately-held, Tucson-based provider of molecular-technology solutions, hired Steve Hagan as vice president of molecular diagnostic sales. Hagan joins HTG Molecular Diagnostics from Ventana Medical Systems, a member of the Roche group,
View HTML
Toggle Summary HTG Molecular Diagnostics Partners with John Wayne Cancer Institute to Commercialize Melanoma Signatures
TUCSON, Ariz. (June 1, 2012) – The John Wayne Cancer Institute (JWCI) at Saint John’s Health Center in Santa Monica, California selected HTG Molecular Diagnostics as an exclusive commercialization partner for recently identified HTG melanoma signature assays which may be useful for diagnostic and
View HTML
Toggle Summary Sam Rua HTG Molecular Diagnostics VP of Regulatory Affairs is Keynote Presenter at TIDES Conference
TUCSON, Ariz. (May 14, 2012) – Sam Rua, vice president of regulatory affairs and quality systems at HTG Molecular Diagnostics, will offer a keynote presentation, “Update on Commercialization of RUO and IUO Products and Oversight of Lab-Developed Tests,” at the 2012 TIDES Oligonucleotide and Peptide
View HTML
Toggle Summary HTG Molecular Diagnostics Hires Vice President of Medical Innovation
TUCSON, Ariz. (April 26, 2012) – HTG Molecular Diagnostics, a privately-held, Tucson-based provider of molecular-technology solutions, hired Chris Roberts as vice president of medical innovation. Roberts joins HTG from Caris Life Sciences where he served as vice president of the oncology division
View HTML
Toggle Summary HTG/Sanofi US Annouce Biomarker Collaboration
HTG Molecular Diagnostics and Sanofi US Collaborate to Identify B-cell Malignancy Biomarkers Development of tests that help identify patients most likely to respond to targeted therapy is a key step toward the personalization of medicine TUCSON, Ariz.
View HTML
Toggle Summary HTG Molecular Diagnostics Adds Three Executive Team Members
February 13, 2012 TUCSON, Ariz. — HTG Molecular , a privately-held, Tucson-based provider of molecular-technology solutions, added three industry-renown professionals to its executive team: Shaun McMeans , Vice President of Finance, Administration and Chief Financial Officer; Timothy J Holzer,
View HTML